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Introduction {#sec001}
============

Hepatitis B virus (HBV) infection can lead to severe disease and death, affecting people worldwide. About 2 billion people worldwide are estimated to have been exposed to HBV, with almost one quarter of them having a chronic infection \[[@pone.0234348.ref001], [@pone.0234348.ref002]\]. Every year, more than half a million HBV-related deaths are recorded all over the world \[[@pone.0234348.ref001], [@pone.0234348.ref003]\]. Reports have often shown disparities in the levels of endemicity of HBV across the world, with Sub-Saharan Africa (SSA) and East Asia among the high-endemic areas where about 5% and 10% of the adult populace, respectively, is chronically infected \[[@pone.0234348.ref003]--[@pone.0234348.ref008]\]. In Europe and America, about 1% of the population is chronically infected. The risk of being infected with HBV in one's lifetime in most countries in Africa and Asia, including parts of the Middle East, is estimated to be more than 60% \[[@pone.0234348.ref005], [@pone.0234348.ref009], [@pone.0234348.ref010]\]. Under-reporting of HBV in Africa makes it difficult to accurately estimate the disease burden, but some estimates suggest that 70--90% of adults showed some evidence of HBV infection and the HBsAg positivity rate is placed at 6--20% \[[@pone.0234348.ref001], [@pone.0234348.ref002], [@pone.0234348.ref009]\].

Individuals with chronic HBV infection have an increased risk of liver disease and hepatocellular carcinoma (HCC). It is estimated that 10 to 33% of all individuals who develop a persistent infection will end up with chronic hepatitis, and among them, 20 to 50% are likely to develop liver cirrhosis \[[@pone.0234348.ref011]\]. HCC is a dangerous cancer with few treatment options that is often a challenge in many third world settings such as Africa \[[@pone.0234348.ref001], [@pone.0234348.ref012]\]. SSA is shown to have one of the highest HBV-related liver cancer rates worldwide \[[@pone.0234348.ref013]\]. HBV-related liver cancer is more prominent among males than females in the African region \[[@pone.0234348.ref005], [@pone.0234348.ref013], [@pone.0234348.ref014]\]. It is also important to mention that the mean age for developing HCC in Africa and other developing regions is younger than what is seen in developed regions such as North America and Western Europe. Therefore, productive years are lost to HCC as a result of HBV infection in SSA \[[@pone.0234348.ref009], [@pone.0234348.ref015], [@pone.0234348.ref016]\].

HBV is a disease of public health importance in Ghana and needs the utmost attention. Ghana is located in SSA, a region noted for high (≥8.00%) prevalence of chronic HBV infection compared with the rest of the world \[[@pone.0234348.ref001], [@pone.0234348.ref009]\]. Some recent reviews have estimated and reported the prevalence of HBV in Ghana \[[@pone.0234348.ref017]--[@pone.0234348.ref019]\]. For instance, a worldwide estimation of HBV prevalence by Schweitzer et al. in 2013 revealed a 12.92% \[[@pone.0234348.ref002]\] prevalence of chronic HBV infection in Ghana derived from 12 studies. Ofori-Asenso and Agyeman reported a 12.3% prevalence derived from 30 studies published before 2015 \[[@pone.0234348.ref020]\]. Neither review covered original studies from all regions in Ghana.

Some other studies have also revealed a varying prevalence rate of HBV in Ghana, from 10 to 15% \[[@pone.0234348.ref002], [@pone.0234348.ref020]\]. A search of the literature revealed that no review specifically summarized data on HBV prevalence in Ghana, as Ofori-Asenso and Agyeman reported a limitation that original research was unavailable for four regions and hence based their reported prevalence on six of the ten regions. This reveals that even though there has been a significant effort to estimate the burden of HBV in Ghana, gaps remain in the available evidence. In 2015, the World Health Organization (WHO) set a target to eliminate hepatitis B by the year 2030 \[[@pone.0234348.ref003]\]. To explore and address any gaps in the available evidence and track the HBV prevalence in Ghana following this declaration \[[@pone.0234348.ref003]\], we conducted a systematic review to compile updated information on the prevalence of HBV in Ghana from November 2015 --September 2019.

Methods {#sec002}
=======

Search strategies {#sec003}
-----------------

The current systematic review was reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) \[[@pone.0234348.ref021]\]. We searched published literature from PUBMED, EMBASE, Google Scholar, and ScienceDirect. The search was conducted using the following keywords: hepatitis B, hepatitis B surface antigen, hepatitis B virus, hepatitis B e antigen, hepatitis B core antigen chronic hepatitis B, HBV, HepB, HBsAg, HBeAg, prevalence, Ghana, and Ghanaian ([S1 File](#pone.0234348.s001){ref-type="supplementary-material"}.). The search terms were used separately and in combination using the Boolean operators "AND" or "OR" as appropriate. The search ranged from November 1st, 2015 to September 30th, 2019. No language limitations were set during the literature search; however, the search was limited to research on humans.

Inclusion criteria {#sec004}
------------------

The inclusion criteria were as follows: (i) studies exclusively done for populations in Ghana; (ii) articles published in peer-reviewed journals; (iii) cross-sectional studies reporting the prevalence of HBV; (iv) study participants from any subpopulation except studies among patients with HBV; and (v) studies focusing on prevalence using the presence of hepatitis B surface antigen (HBsAg) as a biomarker for diagnosis. We used no language restriction. However, we excluded studies that reported other forms of hepatitis than hepatitis B, book chapters, and case reports.

Data extraction {#sec005}
---------------

Two investigators (JA and HW) independently screened the studies according to the titles and abstracts. If the articles met the eligibility criteria, we further read the full text to screen the study. Any discrepancies between investigators were planned to be resolved by a third investigator (YC). However, no such situation arose.

Using a predesigned data extraction form, JA and HW independently extracted the following data from each study: study characteristics, including the name of the primary author, publication year, study design, sample size, methods of testing HBV, and prevalence of HBV. Any discrepancies were resolved by referring to the original publications.

Methodological quality assessment {#sec006}
---------------------------------

The Newcastle-Ottawa scale (NOS) for cross-sectional studies quality assessment tool was adopted and used to assess the quality of each study \[[@pone.0234348.ref022]\]. The tool has three major sections. The first section, graded out of five stars, focuses on the sample selection of each study. The second section deals with the comparability of the study, and the last section deals with the outcomes and statistical analysis of each original study. A total NOS score ranges from 0 to 10. Study scores of 9--10 points were considered very good, 7--8 points as good, 5--6 points as satisfactory and \<5 as unsatisfactory ([S2 File](#pone.0234348.s002){ref-type="supplementary-material"}) \[[@pone.0234348.ref022]\]. Two authors (JA and HW) independently assessed the quality of each original study using the tool. Disagreements between the two authors were resolved through discussion.

Data analysis {#sec007}
-------------

HBV infections were measured with prevalence and 95% confidence interval (CI). The review considered the regional distribution of studies based on the ten old regions and combined the six recently established regions to their mother regions. Thus, Greater Accra, Upper West, Upper East, Ashanti, Eastern, and Central regions stood alone. However, in this study the Northern region consists of Northeast, Savannah, and Northern regions; Brong-Ahafo consists of Bono, Bono East, and Ahafo regions; and the Western region consists of Western and Western North regions.

Meta-analysis with a random effect model was used to pool the prevalence from different homogeneous studies. Heterogeneity was tested using the Q test with p\<0.1 considered as statistical heterogeneity. The degree of heterogeneity was measured with I^2^. Subgroup analysis was done if the presence of substantial heterogeneity was observed (I^2^\> 50%). Due to the heterogeneity among the included studies, meta-analyses were conducted separately according to different populations (pre-school children, adolescents, and adults). A similar rule was applied to the adult population, among whom meta-analyses were conducted according to subpopulations with different characteristics (e.g. blood donors, patients with HIV). A fixed effect cumulative analysis was conducted beginning with the largest sample size and adding subsequent studies in the same order while estimating the relative weight to explore the possible impact of bias from smaller studies on the overall effect size. The point at which any additional study did not show any significant shift on the effect size was considered the cut-off point and the conclusion was then made. Statistical significance was always set at p \< 0.05 except for in the heterogeneity tests. Subgroup analyses (e.g. northern and southern Ghana, urban and rural) were done within each subpopulation when statistical heterogeneity was found. All the meta-analyses were performed with Comprehensive Meta-analysis Software for Academics (standard v. 3).

Ethical approval {#sec008}
----------------

The study did not require ethical approval as it used data retrieved from published studies that are already in the public domain.

Results {#sec009}
=======

Results of study identification and retrieval {#sec010}
---------------------------------------------

[Fig 1](#pone.0234348.g001){ref-type="fig"} records the process and detailed results of the literature search and selection. A total of 150 articles were retrieved from the databases and additional sources in the literature search. Thirty-eight articles were retained for full-text review after the removal of duplicates and ineligible studies based on the titles and abstracts. Of the 38 studies, 21 articles met the inclusion criteria for the systematic review and 19 were finally added to the meta-analysis.

![Flow chart of study search and retrieval process (adopted PRISMA: 2009).](pone.0234348.g001){#pone.0234348.g001}

Basic characteristics of included studies {#sec011}
-----------------------------------------

The studies ([Table 1](#pone.0234348.t001){ref-type="table"}) included in the review had total sample sizes of 29 061 and 28 724 respectively for the systematic review and meta-analysis, respectively, across the country. The largest number of studies (6/21, 29%) was conducted in the Ashanti region while no study was identified in the Upper West region. [Table 1](#pone.0234348.t001){ref-type="table"} shows the details of all studies included in the review, covering nine out of the ten old regions. The majority of the retained studies were conducted for the adult population (18/21, 86%) and urban settings (13/21, 62%). No study was conducted in a male-only population, but 6/21 (29%) were conducted in a female-only population (pregnant women), 4/21 (19%) among patients with HIV, and 3/21 studies (19%) in the blood donor population. Regarding the methodological quality of the included studies, 14%, 76%, and 10% of studies were judged as very good, good, and satisfactory quality, respectively, based on the NOS score, while no study was assessed as unsatisfactory.

10.1371/journal.pone.0234348.t001

###### Summary of the descriptive characteristics of articles included in the study.

![](pone.0234348.t001){#pone.0234348.t001g}

  Authors' details                              Study region    Study population         Age group (mean/range)   Site    Sample size   Test        HBsAg+(%)   Quality assessment
  --------------------------------------------- --------------- ------------------------ ------------------------ ------- ------------- ----------- ----------- --------------------
  **Pre-school children**                                                                                                                                       
  Dassah, 2015 \[[@pone.0234348.ref023]\]       Upper East      Vaccinated children      3.1 yrs                  Rural   104           ELISA       1.90        Good
  Apiung, 2017 \[[@pone.0234348.ref024]\]       Greater Accra   Vaccinated children      1.3 yrs                  Urban   424           ELISA       0.05        Satisfactory
  **Adolescents**                                                                                                                                               
  Dzidzinyo, 2016 \[[@pone.0234348.ref025]\]    Volta           School children          17.4 yrs                 Rural   182           ELISA       14.30       Good
  **Adults**                                                                                                                                                    
  Adoba, 2015 \[[@pone.0234348.ref026]\]        Ashanti         Barbers                  28.2 yrs                 Urban   200           RDT         14.50       Good
  Ephraim, 2015 \[[@pone.0234348.ref027]\]      Ashanti         Pregnant women           27.0 yrs                 Rural   168           RDT         9.50        Good
  Ampah, 2016 \[[@pone.0234348.ref028]\]        Ashanti         Community members        25.3 yrs                 Rural   1323          RDT         8.10        Very good
  Adjei, 2016 \[[@pone.0234348.ref029]\]        Greater Accra   Long-distance drivers    40.6 yrs                 Urban   106           ELISA       14.20       Satisfactory
  Archampong, 2016 \[[@pone.0234348.ref030]\]   Greater Accra   Patients with HIV        41.0 yrs                 Urban   3108          ELISA       8.30        Good
  Kye-Duodo, 2016 \[[@pone.0234348.ref017]\]    Eastern         Patients with HIV        40.0 yrs                 Mixed   320           ELISA       8.80        Good
  Luuse, 2016 \[[@pone.0234348.ref031]\]        Volta           Pregnant women           27.7 yrs                 Urban   208           RDT         2.40        Good
  Lokpo, 2017 \[[@pone.0234348.ref032]\]        Eastern         Blood donors             20--50 yrs               Urban   11 436        RDT         7.20        Very good
  Lokpo, 2017 \[[@pone.0234348.ref033]\]        Volta           Blood donors             18--58 yrs               Urban   4180          RDT         6.90        Very good
  Volker, 2017 \[[@pone.0234348.ref019]\]       Western         Pregnant women           26.3 yrs                 Rural   174           RDT         16.70       Good
  Osei, 2017 \[[@pone.0234348.ref034]\]         Volta           Blood donors             20.0--40.0 yrs           Mixed   576           RDT         7.50        Good
  Helegbe, 2018 \[[@pone.0234348.ref035]\]      Northern        Pregnant women           28.5 yrs                 Urban   3127          RDT         4.20        Good
  Owusu, 2018\[[@pone.0234348.ref036]\]         Ashanti         Patients with jaundice   35.0 yrs                 Urban   155           PCR & RDT   54.20       Good
  Anabire, 2019\[[@pone.0234348.ref037]\]       Northern        Pregnant women           27.8 yrs                 Urban   2071          RDT         7.70        Good
  Boateng, 2019 \[[@pone.0234348.ref038]\]      Ashanti         Patients with HIV        40.9 yrs                 Urban   400           RDT         12.50       Good
  De Mendoza, 2019 \[[@pone.0234348.ref039]\]   Ashanti         Outpatients              26.0 yrs                 Urban   305           RDT         8.50        Good
  Frempong, 2019 \[[@pone.0234348.ref040]\]     Brong-Ahafo     Pregnant women           28.9 yrs                 Mixed   100           ELISA       10.00       Good
  Pappoe, 2019 \[[@pone.0234348.ref041]\]       Central         Patients with HIV        41.0 yrs                 Urban   394           RDT         6.60        Good

ELISA, enzyme-linked immunoassay; HIV, human immunodeficiency virus; PCR, polymerase chain reaction; RDT, rapid diagnostic test.

Overall prevalence of hepatitis B infection {#sec012}
-------------------------------------------

The reported prevalence among the 21 studies in the systematic review ranged from 0.05% to 54.20% ([Table 1](#pone.0234348.t001){ref-type="table"}). The prevalence among the 19 studies included for the meta-analysis ranged from 0.05% to 16.70% ([Table 1](#pone.0234348.t001){ref-type="table"}). Generally, there was diversity in participants' ages; however, about 85.71% of the included studies were conducted in adult populations (\>20 years). Two studies were conducted in children less than five years. The most prevalent age group ranged from 20 to 40 years, as specified in ten studies \[[@pone.0234348.ref017], [@pone.0234348.ref019], [@pone.0234348.ref026], [@pone.0234348.ref029], [@pone.0234348.ref034]--[@pone.0234348.ref036], [@pone.0234348.ref038], [@pone.0234348.ref040], [@pone.0234348.ref041]\]. There was no overall pooled national HBV prevalence for the included studies in the meta-analysis because of the vast differences among study participants.

Prevalence among pre-school children {#sec013}
------------------------------------

Two studies (528 participants in total) reported HBV infection prevalence among pre-school children, at 0.05% and 1.90%. The pooled prevalence was 0.55% (95% CI: 0.02--14.23%) ([S1 Appendix](#pone.0234348.s003){ref-type="supplementary-material"}). There was moderate heterogeneity (I^2^ = 60.84%, p = 0.110) between these two studies.

Prevalence among adolescents {#sec014}
----------------------------

Only one study was conducted in an adolescent population, with 182 participants from a senior high school in a rural setting. The HBV prevalence was 14.30% (95% CI: 9.20--19.37%) ([Table 1](#pone.0234348.t001){ref-type="table"}).

Prevalence among adults {#sec015}
-----------------------

Seventeen studies were considered for the meta-analysis in the adult population with a total sample size of 28 196. The HBV prevalence ranged from 2.45% in the Northern region to 16.70% in the Western region. The pooled prevalence was 8.36% (CI: 7.30--9.60%) ([Fig 2](#pone.0234348.g002){ref-type="fig"}) with a high level of heterogeneity (I^2^ = 86.52%, p\<0.001). Subgroup analyses were conducted, and HBV prevalence was reported according to different subgroups among adult populations. In the subgroup analysis ([Table 2](#pone.0234348.t002){ref-type="table"}), two subgroups (geographic zone and sample size) showed statistically significant differences between groups (p\<0.020).

![Forest plot of hepatitis B infection prevalence rate in the adult population in Ghana from 2015 to 2019.](pone.0234348.g002){#pone.0234348.g002}

10.1371/journal.pone.0234348.t002

###### Analysis of the change in hepatitis B prevalence in different subgroups in the adult population in Ghana (2015--2019).

![](pone.0234348.t002){#pone.0234348.t002g}

  Subgroups                No. of studies (no. of participants)   Pooled prevalence (%) (95% CI)   I^2^ (%)   P-value (subgroup differences)
  ------------------------ -------------------------------------- -------------------------------- ---------- ----------------------------------------------
  **HIV status**                                                                                              0.616
     HIV+                  4 (4222)                               8.91 (6.71--11.73)               69.91      
     HIV-                  13 (23 974)                            8.19 (6.95--9.64)                87.75      
  **Residency**                                                                                               0.273
      Rural                3 (1665)                               10.65 (7.63--14.68)              84.76      
      Urban                11 (25 532)                            7.84 (6.62--9.27)                89.35      
      Mixed                3 (996)                                8.47 (5.89--12.04)               0.00       
  **Pregnancy status**                                                                             0.309      
     Pregnant              6 (5848)                               8.78 (7.42--10.36)               75.91      
     Not pregnant          11 (22 348)                            7.49 (5.78--9.65)                92.70      
  **Test type**                                                                                               0.303
      ELISA                4 (3634)                               9.68 (7.08--13.11)               36.70      
      RDT                  13 (24 562)                            8.06 (6.85--9.45)                88.65      
  **Sample size**                                                                                             0.005[\*\*](#t002fn002){ref-type="table-fn"}
      Large (\>1000)       6 (27 045)                             6.94 (5.80--8.29)                89.84      
      Small (\<1000)       11 (1151)                              9.88 (8.31--11.71)               74.34      
  **Blood donor status**                                                                           0.294      
      Donor                3 (16 192)                             7.20 (5.19--9.92)                0.00       
      Not donor            14 (12 004)                            8.75 (7.38--10.35)               88.52      
  **Zones**                                                                                                   0.018[\*\*](#t002fn002){ref-type="table-fn"}
      Northern             2 (5198)                               5.72 (4.03--8.05)                96.44      
      Southern             15 (22 998)                            8.93 (7.73--10.30)               79.65      

HIV, human immunodeficiency virus; RDT, rapid diagnostic test; ELISA, enzyme-linked immunoassay; CI, confidence interval.

\*\*P-value of subgroup differences \<0.020.

Prevalence of hepatitis B in the general population (community members and outpatients) {#sec016}
---------------------------------------------------------------------------------------

Two studies \[[@pone.0234348.ref028], [@pone.0234348.ref039]\] were conducted in the general population (community members and outpatients) with a total sample size of 1628 participants. The hepatitis B prevalences were 8.10% and 8.50%, with a pooled prevalence of 8.18% (CI: 6.94--9.61%) ([S2 Appendix](#pone.0234348.s004){ref-type="supplementary-material"}). There was no evidence of heterogeneity (I^2^ = 0%, p = 0.818).

Prevalence of hepatitis B among blood donors {#sec017}
--------------------------------------------

A total of three studies \[[@pone.0234348.ref032]--[@pone.0234348.ref034]\] reported HBV prevalence among blood donors with a total sample size of 16 192 participants. The hepatitis B prevalence ranged from 6.94% to 7.50% with a pooled prevalence of 7.17% (CI: 6.78--7.57) ([S3 Appendix](#pone.0234348.s005){ref-type="supplementary-material"}). There was no evidence of heterogeneity (I^2^ = 0%, p = 0.784).

Prevalence of hepatitis B among patients with HIV {#sec018}
-------------------------------------------------

The meta-analysis was based on four studies \[[@pone.0234348.ref017], [@pone.0234348.ref030], [@pone.0234348.ref038], [@pone.0234348.ref041]\] conducted among HIV-positive clients. The total sample size was 4222 participants. The HBV prevalence ranged from 6.60% in the Central region to 12.50% in the Ashanti region. The pooled prevalence was 8.92% (CI: 7.03--11.25, p\<0.001) ([S4 Appendix](#pone.0234348.s006){ref-type="supplementary-material"}). There was moderate heterogeneity among the included studies (I^2^ = 69.91%, p = 0.019). As a result, a further subgroup analysis ([S5 Appendix](#pone.0234348.s007){ref-type="supplementary-material"}) was performed to explore the source of heterogeneity. Statistical variations among the included studies were explained by the type of test used in the diagnosis of HBV (ELISA or RDT) among the study participants. There was, however, no statistical difference between the two subgroups (p = 0.732).

Prevalence of hepatitis B infection among pregnant women {#sec019}
--------------------------------------------------------

Six studies \[[@pone.0234348.ref019], [@pone.0234348.ref027], [@pone.0234348.ref031], [@pone.0234348.ref035], [@pone.0234348.ref037], [@pone.0234348.ref040]\] were conducted among pregnant women with a total sample size of 5848 participants. The prevalence ranged from 2.4% to 16.7% with a pooled prevalence of 7.44% (CI; 4.71--11.55) and p\<0.001 ([S6 Appendix](#pone.0234348.s008){ref-type="supplementary-material"}). The results showed very high heterogeneity (I^2^ = 92.69%, p\<0.001). Further subgroup analysis ([S7 Appendix](#pone.0234348.s009){ref-type="supplementary-material"}) revealed that the year of the study contributed to the heterogeneity of the results. Two studies were conducted in 2019 with a total sample size of 2171. The pooled prevalence was 7.82% (CI: 6.78--9.03). There was, however, no evidence of heterogeneity among these studies (I^2^ = 0, p = 0.404).

Prevalence of hepatitis B among special occupational populations (barbers and long-distance drivers) {#sec020}
----------------------------------------------------------------------------------------------------

Two studies \[[@pone.0234348.ref026], [@pone.0234348.ref029]\] with a total sample size of 306 participants were conducted among special occupation populations. The prevalences were 14.20% (barbers) and 14.50% (drivers), with a pooled prevalence of 14.40% (CI: 10.89--18.79) ([S8 Appendix](#pone.0234348.s010){ref-type="supplementary-material"}). There was no evidence of heterogeneity (I^2^ = 0%, p = 0.943).

Prevalence of hepatitis B among patients with jaundice {#sec021}
------------------------------------------------------

One study \[[@pone.0234348.ref036]\] was conducted among a symptomatically jaundiced population with 155 participants from an urban setting in the Ashanti region. This region is the most populous in Ghana. The study was hospital-based and reported an extremely high HBV prevalence of 54.20% among the study population. Participants who tested positive with PCR, RDT, or both were considered positive for hepatitis B infection.

Cumulative meta-analysis {#sec022}
------------------------

Bias from smaller studies was explored with cumulative analysis, the results from which indicated that smaller studies did not impact HBV prevalence. Results based on precision (large sample size) showed that 8/17 studies with a relative weight of 91.34% estimated a pooled effect of 7. 24% with a 95% CI (6.93 to 7.56%) included the pooled prevalence of 7.45% for the total of 17 studies in the meta-analysis ([Fig 3](#pone.0234348.g003){ref-type="fig"}).

![Cumulative forest plot for the included studies (fixed effects model) in the adult-only population.](pone.0234348.g003){#pone.0234348.g003}

Discussion {#sec023}
==========

This study was conducted with the aim of summarizing the updated national prevalence of HBV in Ghana from 2015 to 2019. However, there was no study identified for the Upper West region and thus, the prevalence of HBV from the remaining regions was summarized according to different populations due to the heterogeneity of participants included. A national survey that covers all regions in the country to estimate the actual burden of the disease in Ghana is needed.

The pooled HBV prevalence was very low (0.55%) among pre-school children. These were children who have been vaccinated against HBV with the pentavalent vaccine. Although there was moderate heterogeneity, the variation in age between studies partly explains this. As the mean age increases from 1.3 years to 3.1 years, the antibodies developed through immunization tend to decrease \[[@pone.0234348.ref023], [@pone.0234348.ref024]\] in individuals and thus older children are at a higher risk of infection. This revelation emphasizes the importance of vaccination and good immunization coverage among Ghanaian children \[[@pone.0234348.ref042]\].

It was noted that Ghana started a national expanded program for hepatitis immunization in 2002 \[[@pone.0234348.ref042]\], which should have reduced the prevalence of HBV infections, especially among adolescents. However, an alarming prevalence of about 14.30% was identified among adolescents in this study. There were not sufficient studies to explore this; however, adolescence is characterized by youthful exuberance, sexual exploitation, body modifications (tattooing, piercing, etc.), and risky sexual behaviors, which are all risk factors for HBV transmission \[[@pone.0234348.ref043]\]. Furthermore, in Ghana, adolescents do not discuss sex openly with their parents; they resort to friends who are as well inexperienced with sexually related matters and may end up in engaged in risky behaviors. This suggests the need for further research to fully explore the cause of the high HBV prevalence in this population, regardless of the national immunization program.

In the adult population, overall HBV prevalence was found to be 8.36% in Ghana based on HBsAg seropositivity. This emphasizes that HBV remains a major public health concern in the country. In contrast, the current prevalence is significantly lower than the prevalence of 12.30% reported by earlier studies \[[@pone.0234348.ref002], [@pone.0234348.ref020], [@pone.0234348.ref044], [@pone.0234348.ref045]\]. However, a similar prevalence rate of 8.50% was reported quite recently in an epidemiological study in 2012 \[[@pone.0234348.ref046]\]. The results of this review are lower than the \>8.80% reported in other parts of West Africa \[[@pone.0234348.ref047]--[@pone.0234348.ref049]\] and the prevalence for the African region at large \[[@pone.0234348.ref002]\]. For instance, a meta-analysis reported that the pooled prevalence of HBV in the Nigerian population is 13.6% \[[@pone.0234348.ref050]\]. A high prevalence was reported among different subgroups as well: 14.0% for blood donors, 14.1% for pregnant women attending antenatal clinics, 11.5% for children, and 14.0% for adults \[[@pone.0234348.ref050]\]. Nonetheless, the results from our study confirm the categorization of Ghana as a high HBV-endemic country (≥8.00%) which exceeds the reported global prevalence rate of 3.61% \[[@pone.0234348.ref001], [@pone.0234348.ref003], [@pone.0234348.ref007]\]. Comparing to other parts of the world, the HBV prevalence rate has been estimated to be \<5.10% in Iraq and 4.00% in Singapore \[[@pone.0234348.ref002]\]. The Middle East, Europe, and North America all reported a rate lower than 2.00% \[[@pone.0234348.ref002]\]. This comparison, therefore, indicates the enormous burden of HBV infection in Ghana.

In the blood donor population, HBV prevalence was 7.17%. Transfusion safety of blood and blood products in Ghana should be a major concern as about one in every ten blood donors is infected with HBV. Our result was lower than the 7.70% and 9.70% reported in Burkina Faso \[[@pone.0234348.ref051]\] and Sierra Leone, respectively \[[@pone.0234348.ref008]\]. However, a much lower risk of HBV infection through blood transfusion (1.4 in 100 000) was reported in Korea \[[@pone.0234348.ref052]\]. Our results showed that rapid diagnostic test (RDT) kits were used in all the studies among blood donors. Furthermore, RDTs are the most commonly used kits in developing countries because of their ease of use and lower cost. Meanwhile, Mutocheluh and colleagues examined five brands of these kits on the Ghanaian market, finding a sensitivity lower than 60% and raising serious concerns for their use in blood donation centers to exclude HBV \[[@pone.0234348.ref053]\]. The present study emphasizes the need for robust screening techniques and uncompromising adherence to the transfusion policy in Ghana which advocates for the need to screen for transfusion-transmissible diseases such as HIV, HBV/HCV, and syphilis.

Among pregnant women, HBV prevalence remains high (7.44%), as reported in other parts of the sub-region \[[@pone.0234348.ref054]\] and thus, mother to child transmission remains a major route of HBV infection in Ghana \[[@pone.0234348.ref055]\]. Comprehensive preconception screening, education, and early initiation of treatment for infected couples can complement the already existing policy on prevention of mother to child transmission in reducing infection risk to the child and also benefit the expectant mothers. Ghana as a country should also consider vaccinating all tested-negative pregnant women as part of the already existing free maternal care service program.

Additionally, this study revealed a very high HBV prevalence of 14.40% among barbers and long-distance drivers. A previous study revealed poor knowledge about HBV transmission among barbers in an urban area in Ghana \[[@pone.0234348.ref056]\] and thus emphasizes the need for education on HBV transmission in this population.

HBV prevalence among patients with HIV was determined to be 8.92%, although this rate is lower than the 13.60% reported in a previous systematic review by Agyeman and Ofori-Asenso in 2016 \[[@pone.0234348.ref018]\]. This prevalence is higher than the WHO's category for high-endemic areas. Moreso, this result suggests a high double disease burden for the affected clients and may lead to dire consequences of liver disease in the already immune-compromised persons. Although HBV testing is now considered among patients with HIV, there exists a gap in giving complete care to this population \[[@pone.0234348.ref042]\]. Patients who test negative for HBV are not protected by way of vaccination and this remains a missed opportunity in reducing the prevalence in the general population.

The WHO's target to eliminate HBV by the year 2030 seems unachievable in Ghana if the trends in the healthcare system are not realigned towards universal care in the face of this high prevalence. Several factors are implicated in the observed high HBV prevalence in Ghana. There still exists an information gap and a lack of understanding among the Ghanaian populace of the transmission dynamics of HBV. Some studies conducted among pregnant women in the Kintampo and Upper West regions reported low awareness and knowledge about HBV transmission \[[@pone.0234348.ref057], [@pone.0234348.ref058]\]. Mkandawire and colleagues pointed out that, in the Upper West region, the populace is even confused about the difference between HBV infection and other diseases like malaria and yellow fever \[[@pone.0234348.ref059]\].

The most efficient and cost-effective way of controlling HBV is by vaccination \[[@pone.0234348.ref003], [@pone.0234348.ref060]\]. Interestingly, the high cost of the vaccine has led to many miss opportunities in various service points in the health system. For instance, negative individuals miss out on vaccination at blood donor centers, antenatal care services, and antiretroviral therapy clinics simply because they cannot afford it. These individuals later become positive and increase the overall disease burden. Furthermore, the cost of the monovalent HBV vaccine given to infants born to reactive mothers is borne by parents; this is another financial barrier that may put the child at risk of infection. A subsidy to the cost of these vaccines would dramatically reduce infection rates.

Strengths and limitations {#sec024}
-------------------------

This current review provides the most updated disease burden figures regarding HBV prevalence in Ghana. As 90.00% of the included studies' methodologies were robust, this result for HBV prevalence can be said to reflect the current situation in Ghana. This study provides the prevalence among children under five years of age which was not identified by previous systematic reviews \[[@pone.0234348.ref002], [@pone.0234348.ref020]\] and thus reaffirms the importance of childhood immunization programs.

There are several limitations to this review. Although we comprehensively searched the literature, an overall national prevalence of HBV could not be determined because we were not able to identify any related publications for the Upper West region. The prevalence determined in this study was therefore based on subpopulations and hence cannot be said to fully represent the general Ghanaian population. Furthermore, most of the studies (13/21, 62%) were conducted in urban settings and in adult populations (18/21, 86%). Hence, the prevalence is more representative of the adult, urban population. The aforementioned information also revealed the research priorities for future studies: HBV prevalence among children and adolescents, in populations from the Upper West region of Ghana, and in rural areas. Due to the limited number of studies included in each meta-analysis, we were not able to explore the potential of publication bias \[[@pone.0234348.ref041]\]. However, a cumulative bias analysis showed that eight (n = 23 094) large included studies contributed about 91.21% of the total prevalence rate and hence the prevalence was not impacted by smaller studies.

Conclusions {#sec025}
-----------

This systematic review and meta-analysis indicated that the prevalence of HBV infection between 2015 and 2019 in Ghana was 0.55%, 14.30%, and 8.36% among pre-school children, adolescents, and adults, respectively. There was a significantly low prevalence among pre-school children and a decline in the adult population in Ghana. There however still remains a high prevalence among adolescents. The burden of chronic HBV infection is also unevenly distributed among the various subpopulations in the adult group and remains high per the WHO's level of categorization. That notwithstanding, HBV eradication is possible by vaccination. To address these challenges of HBV infection among Ghanaians, there is an urgent need for an integrated approach in the health care system continuum. The government and its partner agencies, therefore, need to explore the possibility of a free HBV vaccination policy with the goal of eliminating this disease burden.
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1\. Please ensure that you include a title page within your main document. We do appreciate that you have a title page document uploaded as a separate file; however, as per our author guidelines (<http://journals.plos.org/plosone/s/submission-guidelines#loc-title-page>) we do require this to be part of the manuscript file itself and not uploaded separately.

Could you therefore please include the title page into the beginning of your manuscript file itself, listing all authors and affiliations?

Response to comment:

Thank you for alerting us to this policy. We have added a tittle page to the main manuscript.

2\. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study\'s minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see <http://journals.plos.org/plosone/s/data-availability.Upon> re-submitting your revised manuscript, please upload your study's minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see <http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories>. Any potentially identifying patient information must be fully anonymized.

Response to comment:

Thank you for this comment. We have included all relevant data as Supporting information (S12).

Additional Editor comments:

This is a meta-analysis of HBV infection in Ghana. Given the high prevalence of HBV in West Africa, this is a reasonable study goal. The methods are well described and appropriate. The manuscript should be reviewed carefully by a native English speaker and/or a professional editing service.

Response to comment:

Thank you very much for your comments. We employed a professional proofreading service (Editage) to help in this regard.

Comment 1. It is unclear why only data from 2015 to 2019 were included? Certainly there are studies before that time period that are relevant.

Response to comment 1:

Thank you for your comment. The reason for conducting the study between 2015 and 2019 was informed by the fact that previous meta-analyses has synthesized evidence until 2015 \[1\]. Hence, the prevalence before 2015 was already known. The present systematic review aimed to summarize evidence from after 2015 which was not covered by previous systematic reviews. Also, given that in 2015 the World Health Organization set a target to eliminate hepatitis B by the year 2030 \[1\], this study sought to update the national prevalence, among other objectives, and aimed to track the HBV prevalence in Ghana for the 5 years following this declaration. We have added the aforementioned information to the manuscript to address these comments:

In 2015, the World Health Organization (WHO) set a target to eliminate hepatitis B by the year 2030 \[1\]. To explore and address any gaps in the available evidence and to track the HBV prevalence in Ghana following this declaration \[1\], we conducted a systematic review to compile updated information on the prevalence of HBV in Ghana from November 2015 -- September 2019.

Comment 2: Line 2: Approximately 2 billion people have been exposed to HBV, but there certainly are not that many that are currently infected.

Response to comment 2:

Thank you for your comment. We agree that this is not the number currently infected; we therefore rephrased our statement as follows:

About 2 billion people worldwide are estimated to have been exposed to HBV, with almost one quarter of them having a chronic infection.

Comment 3: It would be helpful to mention and discuss briefly any other meta-analysis of HBV prevalence conducted in other Africa countries -- particularly West Africa -- for comparison.

Response to comment 3:

Thank you very much for your comment; we do agree with you that related studies in parts of West Africa will enhance comparison. Results from a meta-analysis focused on the Nigerian population have been added and compared in the Discussion section. The related revision is as below:

In the adult population, overall HBV prevalence was found to be 8.36% in Ghana based on HBsAg seropositivity. This emphasizes that HBV remains a major public health concern in the country. In contrast, the current prevalence is significantly lower than the prevalence of 12.30% reported by earlier studies. However, a similar prevalence of 8.50% was reported quite recently in an epidemiological study in 2012. The results of this review are lower than the \>8.80% reported in other parts of West Africa \[2-4\] and the prevalence for the African region at large \[5\]. For instance, a meta-analysis reported that the pooled prevalence of HBV in the Nigerian population is 13.6% \[6\]. A high prevalence was reported among different subgroups as well: 14.0% for blood donors, 14.1% for pregnant women attending antenatal clinics, 11.5% for children, and 14.0% for adults \[6\]. Nonetheless, the results from our study confirm the categorization of Ghana as a high HBV-endemic country (≥8.00%) which exceeds the reported global prevalence rate of 3.61 % \[1, 7, 8\].

Reviewers' comments

Reviewer \#1:

Comment 1: The systematic review and meta-analysis done have not added any additional or new information to the prevalence of Hepatitis B in Ghana. This is due to limitations the authors themselves recognized. Studies do not cover the whole population, most studies are small and the number of studies in the heterogeneous populations few over the short period thus the basis for the meta analysis in some cases were two or three studies. The process thus looked more like an academic exercise rather than providing additional scientific knowledge. A previous meta-analysis covered 10 years: Ofori-Asenso R, Agyeman AA. Hepatitis B in Ghana: a systematic review & meta-analysis of prevalence studies (1995-2015). BMC Infect Dis. 2016 Mar 18;16:130. doi: 10.1186/s12879-016-1467-5. PMID: 26987556; PMCID: PMC4797341. Im not sure why the authors choose to do same over five years 2015-2019 instead of fifteen years, 1995 -2019

Response to comment 1:

Thank you for your comments. As mentioned in our response to comment 1 from the Editor, the reason for conducting the study between 2015 and 2019 was informed by the fact that meta-analyses have synthesized evidence until 2015 \[1\]. Hence, the prevalence before 2015 was already known. The present systematic review aimed to summarize evidence from after 2015 which was not covered by previous systematic reviews. Also, as the World Health Organization set a target in 2015 to eliminate hepatitis B by the year 2030 \[1\], this study sought to update the national prevalence, amongst other objectives, and aimed to track HBV prevalence in Ghana for the 5 years following this declaration.

Furthermore, this study revealed new findings about hepatitis B infection in the Ghanaian population. This included the prevalence rate of hepatitis among preschool children which was not revealed by the two previous meta-analyses since 1965, Schweitzer et al. \[5\] and Ofori-Asenso and Agyeman \[9\]. The above studies also stated the limitations in obtaining a nationwide prevalence rate. Schweitzer included only three studies from Ghana and used them to approximate the national prevalence. Additionally, Ofori-Asenso and Agyeman could not find any related studies for four regions of the country and acknowledged that the results could not be said to be the national prevalence. To address this comment, we made revisions in the Introduction and Discussion sections:

Introduction:

In 2015, the World Health Organization (WHO) set a target to eliminate hepatitis B by the year 2030 \[1\]. To explore and address any gaps in the available evidence and to track the HBV prevalence in Ghana following this declaration \[1\], we conducted a systematic review to compile updated information on the prevalence of HBV in Ghana from November 2015 -- September 2019.

Discussion:

There are several limitations of this review. Although we comprehensively searched the literature, an overall national prevalence of HBV could not be determined because we were not able to identify any related publications for the Upper West Region. The prevalence determined in this study was therefore based on subpopulations and hence cannot be said to fully represent the general Ghanaian population. Furthermore, most of the studies (13/21, 62%) were conducted in urban settings and in adult populations (18/21, 86%). Hence, the prevalence is more representative of the adult, urban population. The aforementioned information also revealed the research priorities for future studies: HBV prevalence among children and adolescents, in populations from the Upper West region of Ghana, and in rural areas.

Comment 2: Results-There was no PRISMA diagram. There are no random effect plots

Response to comment 2:

Thank you for your comments. According to the submission guidelines, figures should be uploaded separately. We uploaded the PRISMA diagram as Fig. 1, so it was not embedded in the results. Several random effects plots were uploaded (e.g. Fig. 2 and the supporting figures for all subgroups). They are presented after the main text in the generated PDF file.

Comment 3: Discussion- This needed to have more depth. Ghana started a national expanded programme on Hepatitis immunization in 2002. The high prevalence in adolescents in contrast to children and adults to be put in context. Also the quality or generation of HBsAg tests used should have been analyzed in the Meta analysis to enrich the discussions.

Response to comment 3:

Thank you very much for your comments; it is an important observation that you made. We expected that after the national program of immunization, a reduction in prevalence should be seen among adolescence. However, it is observed that as age increases, the antibody titer decreases. Because there were not sufficient studies to explore this, we propose that the high prevalence of hepatitis B among adolescents was also related to adolescents' risky behavior and parents not openly discussing sexual behavior with teenagers. We linked to this idea in the Discussion section:

It was noted that Ghana started a national expanded program for hepatitis immunization in 2002 \[10\], which should have reduced the prevalence of HBV infections, especially among adolescents. However, an alarming prevalence of about 14.30% was identified among adolescents in this study. There were not sufficient studies to explore this; however, adolescence is characterized by youthful exuberance, sexual experimentation, body modifications (tattooing, piercing, etc.), and risky sexual behaviors, which are all risk factors for HBV transmission \[11\]. Furthermore, in Ghana, adolescents do not discuss sex openly with their parents; they resort to friends who are as well inexperienced with sexually related matters and may end up engaged in risky behaviors. This suggests the need for further research to fully explore the cause of the high HBV prevalence in this population, regardless of the national immunization program.

We agree with you that the quality and generation of HBsAg tests should have been analyzed in the meta-analysis to enrich the Discussion. We analyzed the quality of tests in the subgroup analysis (Table 1), which indicates that ELISAs were more accurate in detecting HBV compared to RDT. However, RDT is the more commonly used test in Ghana's blood donation centers. This certainly attracted our attention, and was emphasized in the Discussion as follows:

Furthermore, RDTs are the most commonly used kits in developing countries because of their ease of use and lower cost. Meanwhile, Mutocheluh and colleagues examined five brands of these kits on the Ghanaian market, finding a sensitivity lower than 60% and raising serious concerns when used in blood donation centers to exclude HBV \[12\]. The present study emphasizes the need for robust screening techniques and uncompromising adherence to the transfusion policy in Ghana which advocates for the need to screen for transfusion-transmissible diseases such as HIV, HBV/HCV, and syphilis.

Reviewer \#2: ACCEPT with some good grammatical revisions please

This is a well-conducted and useful meta-analysis. The methods in the literature search and statistical approaches are appropriate and sound. The subgroup analyses were very revealing in terms of pockets of high-need populations within Ghana. These were clearly linked to explanations within the discussion that describe attributes which predispose to infection and/or increased morbidity (i.e. adolescent sexual practices; HBV detection kids with poor sensitivity in the blood donor population; etc.).

The pooled prevalence itself is sufficient to raise alarm bells, but the extremely high rates in certain populations (adolescents, pregnant women, HIV+) suggest additional need for targeted intervention and care.

Response to comment:

Thank you very much for your comments. We employed a professional proofreading service (Editage) to help in this regard.
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